Valeant to Buy Medicis Pharmaceutical in $2.6 Billion Deal

Lock
This article is for subscribers only.

Valeant Pharmaceuticals International, Inc. said it agreed to buy Medicis Pharmaceutical Corp. in a transaction valued at about $2.6 billion.

Valeant, in what it described as a “definitive agreement,” said it would acquire all Medicis shares outstanding for $44 each in cash. The purchase price represents an approximate 39 percent premium to Medicis’ closing price of $31.56 on Aug. 31 in New York composite trading.